Gyre Therapeutics Inc. (GYRE)vsNovartis AG ADR (NVS)
GYRE
Gyre Therapeutics Inc.
$6.29
-4.30%
HEALTHCARE · Cap: $606.43M
NVS
Novartis AG ADR
$155.41
+1.38%
HEALTHCARE · Cap: $296.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 48237% more annual revenue ($56.58B vs $117.05M). NVS leads profitability with a 23.9% profit margin vs -5.4%. NVS earns a higher WallStSmart Score of 49/100 (D+).
GYRE
Avoid25
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GYRE.
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
2.1% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.2% — below average capital efficiency
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : GYRE
The primary concerns for GYRE are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
GYRE profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
GYRE is growing revenue faster at 2.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 25/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is an innovative biopharmaceutical company dedicated to advancing therapies for rare and complex diseases through its proprietary platform, which integrates gene therapy and precision medicine. The company boasts a promising pipeline focused on addressing significant unmet medical needs and improving patient outcomes. With a strong commitment to scientific excellence and strategic collaborations, Gyre is strategically positioned for impactful growth in the biopharmaceutical landscape. As it continues to enhance its research and development initiatives, Gyre stands to transform treatment paradigms for patients facing challenging health conditions.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?